Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Int J Cancer. 2009 Nov 15;125(10):2465–2473. doi: 10.1002/ijc.24628

Figure 1. Effect of fisetin of AsPC-1 cells on cell growth & viability, cell proliferation and induction of apoptosis.

Figure 1

(A) Cell growth and viability of human PaC AsPC-1cells treated with fisetin (0-80 μM for 24 and 48 h) as measured by MTT assay. Each concentration of fisetin was repeated in ten wells. The values are represented as percent viable cells where vehicle (DMSO)-treated cells were regarded as 100% viable. Data is represented as mean ± SE of three independent experiments. Inset: Structure of fisetin. (B) Histogram showing rate of 3[H]thymidine uptake in AsPC-1 cells treated with fisetin. Cells were subjected to fisetin treatment (0-40 μM) for 48 h, the last 16 h of which was in the presence of [3H]thymidine (0.5 μCi/ml). Each bar represents mean ± SE of three independent experiments. *indicates p<0.05. (C) Effect of fisetin (0-80 μM) treatment on apoptosis induction in AsPC-1 cells as demonstrated by annexin-V staining (green fluorescence). (D) Effect of fisetin (0-80 μM) treatment on the expression and cleavage of PARP as determined by immunoblot analysis. Blots were stripped and reporbed with β-actin for equal protein loading. The immunoblots shown here are representative of three independent experiments with similar results. *indicates p<0.05